NCT01555749View on ClinicalTrials.gov

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 12, 2012

Primary Completion Date

May 8, 2012

Study Completion Date

May 8, 2012

Conditions
Congenital Bleeding DisorderHaemophilia AHaemophilia BHealthy
Interventions
DRUG

NNC172-2021

One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL

DRUG

placebo

One injection administered subcutaneously (s.c., under the skin)

Trial Locations (1)

HA1 3UJ

Novo Nordisk Investigational Site, Harrow

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01555749 - Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects | Biotech Hunter | Biotech Hunter